Releases

Date Title and Summary Additional Formats
Toggle Summary Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2018
Veloxis Upgrades 2018 Outlook Based on Strong Performance Copenhagen, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Highlights Veloxis upgrades 2018 Outlook based on strong performance.   Product revenue for first half of 2018 was USD 17.2 million, an increase of 117% compared to the same period last year.
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program
Company Release no. 13/2018 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 13 July 2018 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue and
View HTML
Toggle Summary Veloxis Partners with the American Society of Transplant Surgeons to Award First Annual ASTS-Veloxis Fellowship in Transplantation
Veloxis Pharmaceuticals A/S is pleased to announce an ongoing partnership with the American Society of Transplant Surgeons (ASTS) to support the fellowship training of a transplant surgeon with the ASTS-Veloxis Fellowship in Transplantation. The award provides two years of financial support.
View HTML
Toggle Summary Correction: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018
Company Release no. 12/2018 To:  Nasdaq Copenhagen A/S  Copenhagen, Denmark, 16 May 2018   Correction: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018   Correction: In the company release titled "Veloxis Pharmaceuticals Announces Financial Results for the
View HTML
Toggle Summary Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018
  Company Release no. 12/2018 To:  Nasdaq Copenhagen A/S  Copenhagen, Denmark, 14 May 2018   Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018   Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Interim Report for the First Three Months of 2018.  This
View HTML
Toggle Summary FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR®
Company Release no. 11/2018 To: NASDAQ Copenhagen A/S                                              Copenhagen, Denmark, 19 April 2018    FDA Accepts Veloxis's Supplemental New Drug Application for the  De Novo  Indication for ENVARSUS XR ®     Veloxis Pharmaceuticals A/S announced today that the
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program
Company Release no. 10/2018 To: NASDAQ Copenhagen A/S                                                 Copenhagen, Denmark, 17 April 2018 Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program   Today, the Board of Directors of Veloxis Pharmaceuticals A/S has decided to issue and
View HTML
Toggle Summary Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2018
Company Release no. 09/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 13 April 2018   Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2018   Summary: At Veloxis Pharmaceuticals A/S' Annual General Meeting held earlier today, all proposals from the Board of Directors were
View HTML
Toggle Summary Veloxis Appoints Morten Marott as Chief Financial Officer
Company Release no. 08/2018 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 03 April 2018   Veloxis Appoints Morten Marott as Chief Financial Officer   Veloxis Pharmaceuticals A/S (OMX: VELO) announced today that Morten Marott is joining the company as its new Chief Financial Officer.  Mr.
View HTML
Toggle Summary Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 March 2018
Company Release no. 07/2018    To: NASDAQ Copenhagen A/S                                             Copenhagen, Denmark, 31 March 2018    Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 March 2018   Veloxis Pharmaceuticals A/S announces, in accordance with
View HTML
Toggle Summary Veloxis Announces the Publication of ASERTAA (A Study of Extended Release Tacrolimus in African-Americans), a Phase IIIb study of ENVARSUS XR®
Investor News no. 01/2018   To: NASDAQ Copenhagen A/S                                             Copenhagen, Denmark, 28 March 2018   Veloxis Announces the Publication of ASERTAA (A Study of Extended Release Tacrolimus in African-Americans), a Phase IIIb study of ENVARSUS XR®   Veloxis
View HTML
Toggle Summary Notice to Convene Annual General Meeting 2018
 Company Announcement no. 05/2018   To: NASDAQ Copenhagen A/S                                    Copenhagen, Denmark, 22 March 2018   Notice to Convene Annual General Meeting 2018   The board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 ("the Company"), hereby convenes the
View HTML
Toggle Summary Veloxis Increases Share Capital in Connection with Exercise of Warrants
Company Release no. 04/2018   To: NASDAQ Copenhagen A/S                                              Copenhagen, Denmark, 16 March 2018    Veloxis Increases Share Capital in Connection with Exercise of Warrants   Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by
View HTML
Toggle Summary Veloxis Files with FDA for the De Novo Indication for ENVARSUS XR®
Veloxis Pharmaceuticals A/S announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) seeking a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant
View HTML
Toggle Summary Veloxis Pharmaceuticals Releases Annual Report for 2017
Company Release no. 2/2018   To: NASDAQ Copenhagen A/S                                          Copenhagen, Denmark, 27 February 2018    Veloxis Pharmaceuticals Releases Annual Report for 2017     Veloxis Pharmaceuticals A/S (OMX: VELO) today published its Annual Report for the financial year 2017.
View HTML
Toggle Summary Veloxis Secures USD 60M in Debt Financing
Company Release no. 01/2018     To: NASDAQ Copenhagen A/S                                                        14 February 2018   Veloxis Secures USD 60M in Debt Financing   Cary, NC, February 14, 2018 -- Veloxis Pharmaceuticals A/S (OMX:VELO), a specialty pharmaceutical company committed to
View HTML